

Redx Pharma

Contract Clinical Scientist

Redx Pharma plc is an exciting biotech company focused on developing novel precision medicines that have the potential to transform treatment in oncology and fibrosis. Redx develops and manufactures small molecule treatments using its world-class medicinal chemistry expertise and lab infrastructure based at Alderley Park, Cheshire UK (former AstraZeneca R&D facility). This is combined with a deep understanding of the molecular biology and genetics underlying diseases with high unmet medical need. Recent successes at Redx include the sale of two preclinical cancer assets to large pharma, one cancer asset entering clinical trials, and nomination of two fibrosis assets for clinical development.

The Role:

Redx Pharma is looking for a Contract Clinical Scientist to support our early development projects (2-3 days per week)

Responsibilities include:

- Develop and design studies to determine the scientific and clinical viability of a particular drug or portfolio of drugs and interpret trial results
- Participate in protocol design, writing and implementation
- Review and interpret medical data and clinical trial data and put forward conclusions
- Ensure there is adequate input into the drug development process from experts in each of the areas of drug development or provide input into one or more of these areas as a technical expert.
- Build relationships with clinical project teams, regulatory and external service providers.

The successful candidate will:

- Bachelor or Masters in a scientific field is required combined with early clinical trials experience, including with PD(L)-1 compounds.
- Experience managing and interpreting the results of clinical trials as well as exposure to writing protocols
- Experience of authoring scientific documents.
- Well-developed interpersonal skills and strong analytical skills
- Sufficient technical and disease area knowledge to be able to liaise with confidence with internal and external partners
- Considerable experience in the pharmaceutical industry
- Experience across phases I - III drug development.

The closing date for applications is 16th October 2020